Drugs / ACTM-838
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06336148 | Jun 2024 → Aug 2025 | cancer | Actym Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-05-30 | Actym Therapeutics, Inc. | Regulatory Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors actymthera.com ↗
Actym Therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to start a Phase 1 clinical trial of its lead drug candidate, ACTM-838. |
| 2024-04-08 | Actym Therapeutics, Inc. | Results Poster: AACR (American Association for Cancer Research), April 5-10, 2024, San Diego CA actymthera.com ↗
A systemically delivered, clinically-ready, attenuated Salmonella Typhimurium strain ACTM-838 alters the tumor microenvironment and provides durable anti-tumor activity in vivo |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-30 | Actym Therapeutics, Inc. | Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors actymthera.com ↗ |
| 2024-04-08 | Actym Therapeutics, Inc. | Poster: AACR (American Association for Cancer Research), April 5-10, 2024, San Diego CA actymthera.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACTM-838 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06336148 ↗ |